Back to results
US 10,117,953 B2Granted
Antibody drug conjugates
AssigneeNovartis AG
InventorsTinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
Claims15
An antibody drug conjugate of the formula
- Ab—(L—(D)m)n
- or a pharmaceutically acceptable salt thereof;
- wherein
- Ab is an antibody or antigen binding fragment thereof that comprises a heavy chain variable region that comprises:
- (a) a VH CDR1 of SEQ ID NO:
- 22, (b) a VH CDR2 of SEQ ID NO:
- 23, (c) a VH CDR3 of SEQ ID NO:
- 24;
- and a light chain variable region that comprises:
- (d) a VL CDR1 of SEQ ID NO:
- 31, (e) a VL CDR2 of SEQ ID NO:
- 32, and (f) a VL CDR3 of SEQ ID NO:
- 33 and specifically binds to an epitope of human cKIT at domains 1-3 (SEQ ID NO:155);
- L is a linker;
- D is a drug moiety;
- m is an integer from 1 to 8;
- and
- n is an integer from 1 to 10.
15 more elements
An antibody drug conjugate of the formula
- or a pharmaceutically acceptable salt thereof;
- wherein
- Ab is an antibody or antigen binding fragment thereof that comprises a heavy chain variable region that comprises:
- (a) a VH CDR1 of SEQ ID NO:
- 22, (b) a VH CDR2 of SEQ ID NO:
- 23, (c) a VH CDR3 of SEQ ID NO:
- 24;
- and a light chain variable region that comprises:
- (d) a VL CDR1 of SEQ ID NO:
- 31, (e) a VL CDR2 of SEQ ID NO:
- 32, and (f) a VL CDR3 of SEQ ID NO:
- 33 and specifically binds to human cKIT, and comprises at least n number of primary amines;
- and n is an integer from 1 to 10.
10 more elements
Dependencies are inferred from the claim text.